



FY2023

Application Guidelines

Strengthening Program for
Pharmaceutical Startup Ecosystem/
Venture Capital Registration
(Third call for proposals)

October 2023

Japan Agency for Medical Research and Development

Division of Technology Transfer,
Department of Intellectual Property and Technology Transfer

Table of Contents

INTRODUCTION	1
1. SUBJECT	1
2. OUTLINE OF PROGRAM AND CALL FOR PROPOSALS.....	1
3. APPLICATION REQUIREMENTS, COMPLIANCE MATTERS, ETC.	3
4. REVIEW METHOD, SCHEDULE, ETC.....	4
5. PROCEDURES FOR APPLICATION, ETC.	7
6. RESTRICTION ON ELIGIBILITY IN PARTICIPATION, ETC.....	9
7. PHARMACEUTICAL STARTUP IN THE SCOPE OF SUPPORT	9
8. CONTACT.....	9

Introduction

Japan Agency for Medical Research and Development (hereinafter referred to as "AMED") implements the program in which investment and support activities startup companies engaged in developing vaccines and therapeutics for infectious diseases based on the vaccine development strategy* and innovative technologies that contribute to the development of pharmaceuticals and other products for diseases other than infectious diseases (hereinafter referred to as "Pharmaceutical Startups") in Japan by venture capitals (hereinafter referred to as "VC") are promoted and in addition while utilizing their knowledge and support functions, the development of the commercial application is supported in Pharmaceutical Startups in "Strengthening Program for Pharmaceutical Startup Ecosystem"(hereinafter referred to as this "Program").

This call for proposals recruits VCs which support Pharmaceutical Startups. VCs who wish to participate in this Program can make an application by following these Application Guidelines. Pharmaceutical Startups which are eligible for Subsidy from AMED shall be separately recruited by a call for proposals.

As this Program is implemented under the government's budget, the contents of the call for proposals or implementation plan, etc. after adoption may be changed or discontinued or the like due to change, etc. of the government policy.

*"Strategy for Strengthening the Vaccine Development and Production System"

(Cabinet Decision on June 1, 2021)

http://www.kantei.go.jp/jp/singi/kenkouiryousenryaku/r030601vaccine_kaihatu.pdf

(in Japanese)

1. Subject

Call for Proposals pertaining to "Strengthening Program for Pharmaceutical Startup Ecosystem/Registration for Venture Capital" (3rd)

2. Outline of Program and Call for Proposals

(1) Background and Program Objectives

Most new drugs in recent years have been developed by pharmaceutical startup companies, and it is startups that were the first to successfully develop vaccines in the pandemic of COVID-19. The development of new drugs requires a large amount of funding, but it is at the moment more difficult to secure the necessary funds in the pharmaceutical startup ecosystem in Japan, compared with those in Europe or the United States.


In response to this situation, under the "Strategy for Strengthening the Vaccine Development and Production System" approved by the Cabinet in June 2021, this Program was established to support Pharmaceutical Startups that develop for practical application of technologies related to vaccines and therapeutics for infectious diseases. Furthermore, in October 2022, the "Priorities for Comprehensive Economic Measures for the Implementation of the "Grand Design and Action Plan for a New Form of Capitalism"(Draft)" included the following statement regarding this Program: "In the future, we will strengthen its support by expanding the scope to include drug discovery fields other than those related to infectious diseases, where it is difficult to raise funds. "

To solve the shortage of large-scale development funds, this Program supports pharmaceutical startup development and commercialization, especially those engaged in non-clinical, Phase I, Phase II or exploratory clinical trials on the condition that they also receive funding from venture capital firms registered by AMED (hereinafter referred to as "Registered VC") specializing in drug development and providing hands-on business management and commercialization support.

In particular, to achieve sufficient sales and growth of pharmaceutical startup, we will actively support plans to commercialize in overseas markets in addition to Japan.

(2) Outline of this Program

In this Program, AMED subsidizes the practical development of pharmaceuticals conducted by Pharmaceutical Startups in which registered VCs invest more than 1/3 of the subsidized costs. This Program makes two stages of calls for proposals, which are Call for Proposals for VC Registered by AMED((i)Call for Proposals for VC), and Call for Proposals for the practical development of pharmaceuticals conducted by Pharmaceutical Startups invested by Registered VCs ((ii)Call for Proposals from Pharmaceutical Startups)



Program Scheme

(3) Outline of the Call for Proposals

In this Call for Proposals, AMED recruits and registers VCs which are suitable for supporting Pharmaceutical Startups engaged in non-clinical, Phase I, Phase II or exploratory clinical trials*¹ and are developing innovative pharmaceuticals. ((2)(i)Call for Proposals for VC).

*1 The scope of this Program is not limited to the clinical trial under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices but clinical studies which confirms the safety or explores the efficacy in healthy subjects or patients.

(4) Registration Period: 2 business years*² from the date of registration

An interim evaluation will be conducted in the second business year, and a review will be conducted to determine whether registration can be renewed based on the status of activities as Registered VC.

There is no limit to the number of times the registration can be renewed, but the longest registration period is until the end of March 2032.

After registration, the status of activities (sourcing activities, investment activities, etc.) will be checked annually. Registration may be rescinded depending on the results of the activities status.

Furthermore, if there is any case which the startup invested by the Registered VC is the target of the grant of Subsidy in this Program, and which is in Subsidized Project Period, at the end of the VC registration period, activities may be continued as a Registered VC only in such a case.

*2 The business year for this Program is from April 1 to March 31 of the following year.

*3 About Call for Proposals from Pharmaceutical Startups

A Pharmaceutical Startup receiving certain investment from a Registered VC may apply for Call for Proposals from Pharmaceutical Startups ((2)(ii)Calls for Proposals from Pharmaceutical Startups) of this Program. A Registered VC is required to use the fund stated in the Application form pertaining to Call for Proposals, and in addition to appoint Hands-on Members stated in the Application form.

3. Application Requirements, Compliance Matters, etc.

(1) Application Requirements for Registered VC

- It is a corporation*¹ having a function of investing in startups as a business, and having a function of supporting Pharmaceutical Startups in commercialization (venture capital, corporate venture capital*²).
- Including its parent company and subsidiaries, it does not fall under an organized crime group, a member of an organized crime group, a company or a person involved with an organized crime group, a corporate racketeer, or any other antisocial force (hereinafter referred to as "Antisocial Forces") or it is not involved with a person pertaining to Antisocial Forces.
- It agrees with the matters set forth in the Registration Agreement*³, and if registered, it will conclude a Registration Agreement.

*1 If the investment function and the commercialization support function are shared with other companies that are a wholly owned parent company and a wholly owned subsidiary, or another company that is controlled by the same person based on service agreement, etc., please notify AMED in advance. After consultation, specify the relationships and roles of multiple institutions, and apply on behalf of the institution that is primarily in charge of this Program. If adopted, a registration agreement will be signed by multiple parties, including related organizations.

*2 Except the case of carrying out direct investment from the main account of a corporation whose major business is not investment.

*3 The Registration Agreement post on the Calls for Proposals page.

Calls for Proposals page: https://www.amed.go.jp/koubo/19/02/1902B_00045.html

(2) Registered VC's Compliance Matters

The Registered VC shall:

- Proactively promote the efforts leading to discovering and supporting of Pharmaceutical Startups in the target technology areas, strengthening of Pharmaceutical Startup Ecosystem in Japan, and strengthening of coordination with global drug development community;
- Build a good relationship with the adopted Pharmaceutical Startup, provide hands-on support pursuant to the support plan submitted, and promote its commercialization in the form which will maximize the value of the adopted Pharmaceutical Startup;
- Maintain healthy cash management and capital policy by the Pharmaceutical Startup during the Subsidized Project Period (so that the Subsidized Project of the Pharmaceutical Startup will not be affected by capital shortage) and aim at the progress of the pharmaceutical development in accordance with the Subsidized Project Plan Sheet and the business expansion of the adopted Pharmaceutical Startup;
- Make efforts to increase the amount of the fund when subsequently establishing a fund;
- Not obtain guidance fees, commissions, or any other consideration for hands-on support or any other support from the adopted Pharmaceutical Startup;
- Not, by leveraging this Program, execute any agreement that will unreasonably restrict the future business development of an adopted Pharmaceutical Startup* ;
- Appropriately protect the information learned in the course of operations such as the business plan, etc. of the Pharmaceutical Startup in which it invests;
- Report the progress of hands-on support periodically (and upon request of AMED) to AMED;
- Cooperate in publication of information such as questionnaire surveys by AMED and posting, etc. of corporate information, activities status, etc. on AMED's website (contents to be posted will be confirmed by you before publication);
- Other matters set forth in Registration Agreement.

* Refer to "Important Notes on Agreements pertaining to Sound Venture Investment In Japan" (March 2018, Ministry of Economy, Trade and Industry, revised March 2020) https://www.meti.go.jp/policy/newbusiness/data/ryuizikou_r.pdf (In Japanese)

(3) Obligations of Payment to AMED

A Registered VC investing in a Pharmaceutical Startup who has received Subsidy grant shall, if having sold shares within one (1) year^{*1} after receiving the Grant Decision of the Subsidy of this Program^{*2}, pay up to 2/3^{*3} of the sales amount to AMED.

*1 If a Pharmaceutical Startup received the Grant Decision of the Subsidy from AMED after adoption or Stage-Gate Go decision, within one (1) year from such date

*2 It excludes sell-off to a pharmaceutical company (Those who have obtained authorization of marketing authorization or manufacturing of pharmaceuticals, or marketing authorization or manufacturing of regenerative medicine products under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960) or those who are engaged in research and development of pharmaceuticals or regenerative medicine products.)

*3 $\text{Payment amount} = \text{sales amount} \times \left\{ \frac{\text{subsidy amount under this Program}}{\text{subsidy amount under this Program} + \text{total amount of investment by Registered VC}} \right\}$

(4) Deregistration of registered VC

Registration may be rescinded in any of the following cases:

- (i) If application requirements referred to in the above-mentioned (1) are no longer conformed to;
- (ii) if compliance matters referred to in the above-mentioned (2) are found to be not complied with;
- (iii) if the obligations of payment set forth in the above-mentioned (3) are imposed on a Registered VC who invests in an adopted Pharmaceutical Startup as a Lead VC;
- (iv) if it is found there is falsehood in Application Documents;
- (v) if Registered VC is not substantially utilized this Program for a certain period of time;
- (vi) if AMED finds it extremely inappropriate to continue registration;
- (vii) if otherwise falling under any of the matters set forth in Registration Agreement.

4. Review Method, Schedule, etc.

(1) About the Method of review

Upon adoption of a VC in this Program, preliminary evaluations (reviews) shall be conducted by Evaluation Committee members comprising external experts appointed by the President of AMED. The Evaluation Committee will evaluate the stipulated evaluation items, based upon which AMED adopts the Registered VCs.

(A) A review shall be conducted in private by an Evaluation Committee established by AMED. Please note that we cannot answer questions regarding the progress of the review and review itself.

(B) The Evaluation Committee shall make evaluation by conducting a document review of the content of the submitted Application Documents and conducting reviews by interview as necessary and deliberating. Please note that, during the review process, the submission of additional materials may be requested.

(C) In the formal examination, the following cases will not be accepted:

- ① If the applicant does not meet the application requirements
- ② If the Application Documents required for application are incomplete

(D) Following the completion of reviews, AMED will send a notification of review results to the applicant.

(E) Confidentiality obligation will be imposed on Evaluation Committee members with the purpose of prohibiting divulgence or misappropriation of any secret information learned during the course of their duties, including after they retire from these duties.

(F) The corporate names of adopted VCs will be published at the time of publication on AMED's website, etc. Furthermore, the names of Evaluation Committee members shall be published on AMED's website, etc. after the publication of adoption results.

(G) From the standpoint of conducting fair and transparent evaluations, management of conflict of interest for Evaluation Committee members shall be implemented in accordance with AMED's By-Law Regarding the Treatment of Conflict of Interest

Management for Members of the Research & Development (R&D) Project Review Panel. In the case that any of the following items apply to an Evaluation Committee member, they are required to report to AMED that they are subject to management of conflict of interest and as a general rule shall not be involved in evaluation of the relevant project.

- (i) The evaluatee is a family member/relative of the Evaluation Committee member.
 - (ii) The evaluatee is affiliated with the same department at a university, the National Research and Development Agency, or a national research institute or other research institution or business enterprise as the Evaluation Committee member.
 - (iii) The evaluatee has worked closely with the Evaluation Committee member on a joint research project within the past three (3) years including the fiscal year in which the Evaluation Committee evaluation is conducted.
 - (iv) The Evaluation Committee member and the evaluatee have a close teacher-disciple relationship wherein one provided guidance and instruction regarding the other's doctoral thesis.
 - (v) The Evaluation Committee member has received economic benefits from the evaluatee within the past three years, including the fiscal year in which the Evaluation Committee evaluation is conducted, of more than one million yen.
 - (vi) The Evaluation Committee member is in a direct competitive relationship with the evaluatee.
 - (vii) Other serious conflicts of interest are recognized to exist.
- (H) Program applicants and persons intending to apply for the program are prohibited from lobbying AMED executive officers and staff members, PS, PO, or Evaluation Committee members regarding evaluation or adoption.

(2) Evaluation Items

- Conformity to Program Objectives
 - Corporate outline, key area as a VC, investment achievements, investment indexes, etc.
- Ability to carry out fundraising
 - Outline of the fund scheduled to be utilized in this Program, investment capacity, future fund establishment plan, etc.
- Sourcing capability
 - Contents and achievements of sourcing activities in the drug discovery field (development program, financial support during seed stage and early stage, Entrepreneur in Residence, wet lab, office leasing, etc.), due diligence ability, status of investment under review, etc.
- Hands-on capability
 - Providing integrated support and timely and appropriate advice according to the growth stage of Pharmaceutical Startups from the following perspectives:
 - 1) Management perspective
Business planning (global business strategy, capital policy, financing and operation plan, Exit strategy (especially M&A)), internal management, progress management, public relations and external communication, human resource support, introduction to pharmaceutical companies, etc. and other sales channels.
 - 2) Perspectives on development and technology
POC acquisition, resolution of technological issues (formulation, mass production, etc.), securing competitive advantage (intellectual property strategy, differentiation strategy, etc.), CMO/CDMO and CRO collaboration, etc.
 - 3) Regulatory Affairs Perspective
FDA/PMDA compliance, GCP compliance, GMP compliance, etc.

In reviewing the above-mentioned items, the following points are mandatory requirements.

- (i) Investing 1/3 or more of its total investment as a VC in the drug discovery field in the last 5 years.
(If the applicant has a fund specialized in investing in the drug discovery field, or if the applicant is evaluated as capable of providing particularly high-quality support to Pharmaceutical Startups in the evaluation items, the applicant will be considered for reviewing even if the applicant does not satisfy (i)).
- (ii) The applicant must have a track record of supporting clinical trials conducted by the Pharmaceutical Startup in which it has invested as a Lead VC.

(In the cases of a newly established VC or fund, the requirement (ii) may be subject to review in light of the past performance of the individual^{*1} to whom the VC belongs.)

(iii) The applicant must have a track record of dispatching directors to the Pharmaceutical Startups in which it has invested as a Lead VC.

(In the case of a newly established VC or fund, the requirement (iii) may be subject to review in light of the past performance of the individual^{*1} to whom the VC belongs.)

(iv) Members^{*2} who make investment decisions or provide expert advice on investment decisions as hands-on members have experience in drug development at pharmaceutical companies, etc. (regulatory affairs, BD (business development), development planning, etc.) or have important experience (review by organizations such as PMDA and FDA, etc.) in advancing drug development.

(v) Members^{*2} who make investment decisions or provide expert advice on investment decisions as hands-on members have experience in global drug development (experience in conducting global clinical trials, experience in providing hands-on support for global clinical trials, etc.).

*1 Members who make investment decisions or provide expert advice on investment decisions as hands-on members.

*2 General partner, partner, etc.

(3) Publication and Notification of Adoption Results

- The corporate names of Registered VCs will be published at a later date on AMED’s website, etc. Furthermore, AMED will separately send notification of review results to the applicants.
- Upon adoption, various conditions may be imposed.
- The names of Evaluation Committee members shall be published on AMED’s website, etc. at the time of publication.

(4) Schedule

The period of acceptance of Application Documents and selection schedule in this Program is, as at the time that the call for applications opens, planned as follows.

Period of acceptance of Application Documents/selection schedule (Please be sure to bear in mind Notes 1. to 6.)	
Period of acceptance of Application Documents	From Friday, October 6, 2023 to Wednesday, November 22, 2023 at noon (JST)(Observe strictly) * Manifestation of Intention to Apply Deadline: Wednesday, November 15 at noon (Observe strictly) * Deadline for uploading of Application Documents: Wednesday, November 22 at noon (Observe strictly)
Document Review	Early to late December 2023 (planned)
Hearing review (Interview)	January 19th (Friday), 24th (Wednesday), 26th (Friday), 2024 (scheduled)
Notification of review results	Late February 2024 (planned)
Conclusion of registration agreement (Start of registration period)	April 1, 2020 (planned)

(Note 1) For all Application Documents, the documents received after the deadline will not be accepted.

- (Note 2) If not completed correctly, Application Documents may not be accepted.
- (Note 3) After the period of acceptance of Application Documents has ended, AMED may contact the applicants by e-mail or telephone, etc., to confirm administrative details. Please respond to such requests for confirmation promptly using the methods designated by AMED (if AMED does not receive a response, the application in question may be ineligible for review.).
- (Note 4) Hearing reviews may sometimes be conducted over the Internet etc..
- (Note 5) For VC applicants subject to reviews by interview, AMED will contact the applicants by e-mail no later than one week before the hearing review is to take place. In the case that the application is not eligible for a hearing review or hearing reviews themselves are not being conducted, the applicant will not be contacted. Please wait to receive your Notification of Review results.
- (Note 6) Please note that we cannot answer questions regarding the eligibility of individual applications for hearing reviews.

5. Procedures for Application, etc.

Prepare the Application Documents in accordance with the Application Guidelines, and make an application based on the method of submission stated below by the submission deadline. The Registration Agreement and Explanation for Call for Proposal, and Frequently Asked Questions (FAQ) is posted on the Calls for Proposals page (refer to (2) below). Please ensure to read them before the preparation of Application Documents.

(1) Submission Deadline

1. **Deadline for manifestation of intention to apply:
Wednesday, November 15 at noon (Observe strictly)**
2. **Deadline for uploading of Application Documents:
Wednesday, November 22 at noon (Observe strictly)**

* Personal submission, submission by fax and submission without the manifestation of intention to apply by the due date will not be accepted.

(2) How to Obtain Application Documents

Please download Application Forms from the Calls for Proposals page below.
https://www.amed.go.jp/koubo/19/02/1902B_00045.html

(3) Proposal Documents Necessary for Application

No.	Mandatory/Optional	Necessary Proposal Documents	Method for Obtaining
1	Mandatory	Application Form (Word)	Download from the Calls for Proposals page
2	Mandatory	Application Form Attachment (Excel)	Download from the Calls for Proposals page
3	Mandatory	Articles of Incorporation	
4	Mandatory	Materials on the fund prospectus, or investment product overview, etc.	
5	Optional	Other existing materials	

* Please ensure to read "Read This Before You Prepare Application" of the beginning of the Application Form (Word).

(4) Method of Submission

- As manifestation of intention to apply, please send to v-eco"AT"amed.go.jp (Replace "AT" with "@") (i)corporation name, (ii)contact person name, (iii)contact telephone number, and (iv)contact e-mail address. Make the subject "Strengthening Program for Pharmaceutical Startup Ecosystem (Venture Capital Registration). "

(Deadline: November15 (Wed) at noon)

- We will later send you a guidance for Uploading Test together with the URL for submission of Application Documents. Upload the Application Documents by the deadline after Uploading Test.

(Deadline: November22 (Wed) at noon)

- **Please allow yourself for enough time for manifestation of intention to apply and uploading.**
- Application Documents are the 6 or 7 file stated in "III. Checklist Pertaining to Files to be Uploaded (to be submitted) " of "Read This Before You Prepare Application" of the beginning of "Application Form" (Word file).
- Do not password protect files.
- Make the file name "VC23" and "_ (under score)" and "corporation name (can be abbreviated) except Kabushiki Kaisha" and "Document Title."
E.g.: VC23_AMED_Document Title. (extension)
- If you resubmit in the deadline due to unavoidable reasons, please add a number (second: 2) to the end of the file name to indicate the number of submissions and upload again. Please make sure that the file is the latest version at the time of applications deadlines.
- After the deadline for uploading Application Documents, we will contact your contact person by e-mail when accepting the submitted Application Documents in about one week.

(5) If Acceptance of Application Documents and Application Form, etc. is not complete

- Submitted Application Documents will not be returned.
- Application whose uploading is not completed or for which AMED is not able to be accepted within the deadline will not be accepted.
- Application Documents from a person who does not satisfy the application requirements or incomplete proposal documents will not be accepted.
- If Application Documents are incomplete and not corrected by the submission deadline, the application will be invalid.

(6) Language for Application Forms

The Application Form and Application Form Attachments should be written in Japanese or English.

If foreign languages are used in other Application Documents, please use English.

(7) Purpose of use of information

In addition to reviewing applications as part of the selection process, information included in Application Documents regardless of whether they are adopted or not, shall be used in analysis of research trends or macro analysis that contributes to the operation of the AMED program management, such as the creation of new programs.

It should be noted that in order to prevent the rights and interests of the applicants submitting applications or their affiliated institutions from being unfairly infringed, the information acquired shall be used solely for the work detailed above.

In addition, with regard to the information included in Application Documents regardless of whether they are adopted or not, AMED shall manage it in line with laws and ordinances related to the management of corporate documents, protection of personal information and disclosure of information, and the AMED regulations the confidentiality of secret information included in Application Documents shall be strictly maintained to ensure that the rights and interests of the applicants submitting applications or the institutions to which they are affiliated are in no way unfairly infringed. For details, please refer to the Ministry of Internal Affairs and Communications website*.

* Public records and archives management system (Cabinet Office)

<https://www8.cao.go.jp/chosei/koubun/index.html> (in Japanese)

Act on the Protection of Personal Information, etc. (Personal Information Protection Commission (PPC))

<https://www.ppc.go.jp/personalinfo/> (in Japanese)

Information Disclosure System (Ministry of Internal Affairs and Communications)
https://www.soumu.go.jp/main_sosiki/gyoukan/kanri/jyohokokai/index.html
(in Japanese)

6. Restriction on Eligibility in Participation, etc.

- (1) Restrictions on VCs whose application to and eligibility for participation in other competitive research funding programs, etc. has been restricted

With regard to VCs who have been found to have carried out misconduct under research funding programs (including but not limited to competitive research funds, etc. and management expenses grants) (including programs for which new applications are solicited in FY2023 or later, and programs completed in or before FY2022) other than this Program, which are under the jurisdiction of the national government or an independent administrative agency and are government-financed either wholly or in part, and whose application to and eligibility for participation in these programs has been restricted, application to and eligibility for participation in this Program shall also be restricted for the duration of the restrictions imposed. In the case that the relevant VC's application to or participation in this Program becomes known after adoption or registration in this Program, adoption or registration may be cancelled.

- (2) Cases in which it is suspected that misconduct has occurred under another competitive research funding program

In the case that there is a complaint, etc. that a VC participating in this Program is suspected of perpetrating misconduct under another competitive research funding program (including completed programs), the VC is obligated to report to AMED that a formal investigation of the relevant misconduct allegations has been implemented. Please note that, on receipt of this report, AMED may rescind of Adoption or registration.

7. Pharmaceutical Startups in the Scope of Support

Regarding Pharmaceutical Startups eligible for support by this Program, please check the Application Guidelines of Call for Proposal from Pharmaceutical Startups that will be announced in the future. VCs that have been adopted and registered in this call for proposal can apply after the conclusion of Registration agreement.

For an overview of past Call for Proposal from Pharmaceutical Startups, please refer to the project website*.

* Program website <https://www.amed.go.jp/program/list/19/02/005.html>

The Call for Proposals from Pharmaceutical Startups is scheduled to be held periodically several times a year.

The retroactive period for investments from Registered VCs is from November 8, 2022 (Date of Cabinet decision on the FY2022 supplementary budget) until the time of application.

8. Contact

If you have inquiries, etc. with regard to the contents stated in the Application Guidelines, please contact the Divisions and Departments as indicated in the table below^{*1}. In addition, if there is any update to the information, it will be posted on the Calls for Proposals page^{*2}, so please refer to it as well.

Please be sure to check the Explanation for Call for Proposal and Frequently Asked Questions (FAQ) before contacting us. Please note that simply making an inquiry does not constitute an indication of your intention to apply.

*1 If you have any inquiries, please contact us by e-mail. (Replace "AT" with "@" in the e-mail address below.). We do not answer any inquiries by telephone.

*2 https://www.amed.go.jp/koubo/19/02/1902B_00045.html

Contents of inquiries	Contact details
Call for proposals, evaluation, how to fill out the Application Documents, etc.	Division of Technology Transfer, Department of Intellectual Property and Technology Transfer, AMED E-mail: v-eco"AT"amed.go.jp * Make the subject of the e-mail "Strengthening Program for Pharmaceutical Startup Ecosystem (Registration of Venture Capital)," and state the contact details for the reply (corporation name, contact person name, telephone number and e-mail address) in the body text.
Misconduct, Misuse, Fraudulent Use	Division of Research Integrity and Legal Affairs, Department of Research Integrity and Project Management, AMED E-mail: kouseisoudan"AT"amed.go.jp
Conflict of Interest (COI) Management	Division of Research Integrity and Legal Affairs, Department of Research Integrity and Project Management, AMED E-mail: kenkyuukousei"AT"amed.go.jp



Japan Agency for Medical Research and Development

Division of Technology Transfer,
Department of Intellectual Property and Technology Transfer

21F, Yomiuri Shimbun Building 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004

October 2023